A product of Darmiyan
BrainSee Is A
Medical Software
BrainSee is a cloud-based clinical software designed to help physicians with evaluating the prognosis of patients who have amnestic mild cognitive impairment (aMCI).
BrainSee uses a novel AI algorithm that processes a patient’s clinical data (see details below) and provides a score between 0 and 100 (lower is better) that helps doctors with evaluating the patient’s likelihood of progression from mild cognitive impairment to Alzheimer’s dementia in the next 5 years.
Novel technology behind BrainSee
BrainSee was designed and developed based on 40 years of cutting edge neuroscience, artificial intelligence (AI), and a curated collection of thousands of real patient data. BrainSee algorithm processes the patient’s brain MRI scan, pulling critical information that is physiologically relevant to the brain tissue degeneration, and combines it with clinical cognitive test scores to provide a prognostic insight to the physician. Such insight helps doctors choose the best course of treatment or interventions.
Why use BrainSee instead of PET or CSF biomarkers?
Because BrainSee is …
Non-invasive
Convenient
Accurate
Affordable
Available
Scalable
Users: Medical Doctors
BrainSee is essential for any clinician who evaluates patients with mild cognitive impairment. These clinicians generally include geriatricians, neurologists, psychiatrists, family physicians, and primary care physicians.
Target patients: Mild cognitive impairment
These patients …
- have memory concerns and cognitive impairments today.
- may or may not have Alzheimer’s disease.
- may or may not progress to Alzheimer’s dementia in the future. They may stay stable or even improve.
Benefits of BrainSee
- For lower-risk patients, reassurance can be provided without having to go through invasive tests such as lumbar puncture for CSF biomarker measurements, or amyloid PET (radiotracer injection, radiation exposure, high cost, low accessibility, low positive predictive value). BrainSee can be repeated annually if patient & doctor want continued reassurance and monitoring.
- For higher-risk patients, early interventions (medications, lifestyle changes) may postpone the onset of dementia. Life and care planning can be started early. BrainSee can be repeated quarterly if patient & doctor request additional and continued evaluation.
- For doctors, BrainSee enables a data driven approach to diagnostic/ prognostic decision making; increases workflow efficiency; and facilitates a quantitative assessment of the patient’s status with patients and family members.
Inputs & Output
Inputs:
– Brain MRI (standard 3D T1, no contrast injection, no radiation)
– Cognitive test scores (MMSE & CDRSB)
Note: BrainSee inputs are part of current clinical workup of mild cognitive impairment patients. No extra burden.
Output: An PDF report that provides a prognostic score and instructions on how to interpret it.
FDA status
Breakthrough designation May 28, 2021.
Now pending marketing approval.
BrainSee Stories
